CareGuidePro, a New Mobile App and Online Platform for Patients to Navigate Their Spinal Cord Stimulation Journey

CareGuidePro, is a mobile application and web portal that serves as a virtual guide for patients throughout their Medtronic spinal cord stimulation therapy journey.

The patient’s care team, including physicians and Medtronic, may also use the CareGuidePro platform to help manage and support the patient’s experience with spinal cord stimulation. Patients also have the ability to record their pain relief and other feedback directly into the app, providing detailed Patient Reported Outcomes (PROs) to ensure timely, essential information is recorded and accessible even outside of in-person office visits.

“Pain management is a complex and intensely personal experience for individual patients. Every patient is a singular case. The ability to monitor patients more closely, to receive data and feedback more quickly, means we can adjust and adapt therapies more efficiently and effectively when needed,” said Krishnan Chakravarthy, M.D., Ph.D., a San Diego-based interventional pain management physician and first physician to use the technology with patients. “This is an important step forward for the field of neuromodulation and patient care.”

“Knowledge is power, and digital health solutions like CareGuidePro give patients the tools they need to ask the right questions and make informed care decisions, which we know can lead to better long-term outcomes,” said Nandan Lad, M.D., Ph.D., professor of neurosurgery at Duke University and co-founder of Higgs Boson Health. “By providing patients with the right information at the right time, we also aim to reduce inefficiencies and free up care teams to focus on providing outstanding care.”

“CareGuidePro is Medtronic’s first patient-centric digital health platform created for spinal cord stimulation patients, intended as a seamless solution that will naturally integrate into the care provider’s workflow,” said Dave Anderson, president of the Neuromodulation business, which is part of the Neuroscience Portfolio at Medtronic. “We believe this digital health platform will facilitate a more informative and engaging patient experience that will translate into better physician-patient dialogue, potentially contributing to better therapy management.”

CareGuidePro features include:

  • Caregiver access for patients less familiar or able to manage the app, enabling easy access to essential information
  • Procedure-specific FAQs and task lists/reminders
  • Standardized and Custom Patient Reported Outcomes (PRO) surveys
  • Secure sharing of PROs to keep entire care team informed
  • Secure, encrypted two-way communication and file-sharing

Medtronic is currently enrolling patients for the app’s limited commercial release, with a full United States release expected in late summer. CareGuidePro is available on iOS® and Android™ devices.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.